A Multicenter Study to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
Enrolling By Invitation
18 years - 99 years
All
Phase
3
8 participants needed
1 Location
Brief description of study
Were doing this study to see how T-Guard works compared to ruxolitinib to treat aGVHD that doesnt get better with steroids. We want to know if T-Guard and ruxolitinib therapy will make aGVHD go away completely after 28 days.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Steroid-Refractory Acute Graft Versus Host Disease
-
Age: 18 years - 99 years
-
Gender: All
Male or Female, Age 18 or older, Patient has undergone first allo-HSCT from any donor source or graft source.
Updated on
04 Aug 2024.
Study ID: 850922
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
